Details of the Drug Reposition

General Information of This Drug (ID: DMSGA6Z)

Drug Name
Toripalimab   DMSGA6Z
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved in China Indication(s)
Indication Name Indication ID ICD-11 Status REF
Demodex blepharitis DISDSJDZ 1G07 Approved in China [1]
Melanoma DIS1RRCY 2C30 Approved in China [1]
Urothelial carcinoma DISRTNTN 2C92.0 Approved in China [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Esophageal squamous cell carcinoma DIS5N2GV 2E60.1 Phase 3 [2]
------------------------------------------------------------------------------------

References

1 Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
2 ClinicalTrials.gov (NCT03829969) A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Compare Toripalimab Injection (JS001) Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in Treatment of Advanced or Metastatic Esophageal Squamous Cell Cancer (ESCC) Without Previous Systemic Chemotherapy. U.S.National Institutes of Health.